Celltrion
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Celltrion is a Korean biopharmaceutical company that develops and makes biosimilars, which are more affordable versions of biologic medicines whose patents have expired.
It produces antibody-based treatments for cancers and autoimmune conditions and supplies them to markets around the world, often through partners. The company also works on its own novel drugs and runs large biologics manufacturing facilities in Korea.
Summary is AI-generated and may contain errors · figures from DART filings
Biosimilars are follow-on versions of biologic drugs, a different business from the small-molecule generics most people picture.
Celltrion in five facts
What does Celltrion do?
Celltrion is a Korean biopharmaceutical company that develops and makes biosimilars, which are more affordable versions of biologic medicines whose patents have expired.
Where is Celltrion listed and in which sector?
Celltrion (Korean name: 셀트리온) trades under KRX code 068270 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Celltrion?
Its market capitalisation was US$34.6B on 2026-10-21, which puts it in this site's large-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Celltrion's latest annual revenue and operating profit?
For fiscal year 2025, Celltrion reported revenue of US$3.1B, operating profit of US$881.9M and net income of US$778.5M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 17.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Treasury share acquisition: results reportTreasury Shares · Oct 20
- DisclosureOct 14
- Operating results (consolidated) (preliminary) (fair disclosure)
Celltrion filed provisional (unaudited) consolidated results for Q3 2026: revenue of US$1.12B (+45.77% year on year) and operating profit of US$380M (+69.21% year on year).
Earnings · Oct 12 - Material event report (treasury share acquisition)
Celltrion disclosed a plan to buy back its own shares worth US$74M, about 0.2% of its market value.
Treasury Shares · Sep 29 - DisclosureSep 23
- Report on large shareholdings (5% rule) (standard)Sep 23
- DisclosureSep 21
- Share cancellation decisionSep 16
- Treasury share acquisition: results reportTreasury Shares · Sep 16
- DisclosureSep 7
- DisclosureSep 7
- Matter subject to ad-hoc disclosure (fair disclosure)Aug 31
- Material event report (treasury share acquisition)
Celltrion disclosed a plan to buy back its own shares worth US$73.2M, about 0.2% of its market value.
Treasury Shares · Aug 31 - [Amended] Operating results (consolidated) (preliminary) (fair disclosure)
Celltrion updated its previously filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$952M (+44.95% year on year), operating profit of US$309M (+86.31% year on year) and net income of US$254M (+486.57% year on year).
Earnings · Jul 27 · 2 versions - Treasury share acquisition: results reportTreasury Shares · Jun 30
- Material event report (bonus issue)Capital raise · May 21
- Material event report (treasury share acquisition)
Celltrion disclosed a plan to buy back its own shares worth US$66.5M, about 0.2% of its market value.
Treasury Shares · May 21 - [Amended] Decision to acquire shares/equity in another company
Celltrion updated the disclosed terms of an acquisition of Celltrion USA, Inc., now worth US$515M.
M&A · May 11 - [Amended] Rights offering (paid-in capital increase) decision (subsidiary)Capital raise · May 11
- Treasury share acquisition: results reportTreasury Shares · May 8
- Operating results (consolidated) (preliminary) (fair disclosure)
Celltrion filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$793M (+36% year on year), operating profit of US$223M (+115.41% year on year) and net income of US$242M (+222.93% year on year).
Earnings · May 6 - Material event report (treasury share acquisition)
Celltrion disclosed a plan to buy back its own shares worth US$67.7M, about 0.2% of its market value.
Treasury Shares · Apr 22 - Supply contract signed
Celltrion disclosed a supply contract, worth US$198M, about 8.29% of its recent annual revenue, running through Dec 2029.
Supply contract · Mar 17 - Operating results (consolidated) (preliminary) (fair disclosure)
Celltrion filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$911M (+25.06% year on year), operating profit of US$325M (+141.94% year on year) and net income of US$362M (+124.11% year on year).
Earnings · Feb 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Celltrion reported consolidated results for FY2025: revenue of US$2.85B (+17.01% year on year), operating profit of US$800M (+137.49% year on year) and net income of US$706M (+146.25% year on year).
Earnings · Feb 5 - Material event report (treasury share disposal)Treasury Shares · Jan 21